Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingzhu, Chi, Yihebali, Hu, Chuanxiang, Chen, Xiaohong, Ge, Minghua, Zhang, Yuan, Guo, Zhuming, Wang, Jun, Chen, Jie, Zhang, Jiewu, Cheng, Ying, Li, Zhendong, Liu, Hui, Qin, Jianwu, Zhu, Jingqiang, Cheng, Ruochuan, Xu, Zhengang, Li, Dapeng, Tang, Pingzhang, Gao, Ming, Zheng, Xiangqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722716/
https://www.ncbi.nlm.nih.gov/pubmed/36483043
http://dx.doi.org/10.3389/fonc.2022.852032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722716/
https://www.ncbi.nlm.nih.gov/pubmed/36483043
http://dx.doi.org/10.3389/fonc.2022.852032

Ejemplares similares